HomeCompareASCJF vs ABBV

ASCJF vs ABBV: Dividend Comparison 2026

ASCJF yields 105.08% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $37.1K in total portfolio value· pulled ahead in Year 9
10 years
ASCJF
ASCJF
● Live price
105.08%
Share price
$0.14
Annual div
$0.15
5Y div CAGR
-38.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.2K
Annual income
$259.96
Full ASCJF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ASCJF vs ABBV

📍 ABBV pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASCJFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASCJF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASCJF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASCJF
Annual income on $10K today (after 15% tax)
$8,931.68/yr
After 10yr DRIP, annual income (after tax)
$220.97/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,835.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASCJF + ABBV for your $10,000?

ASCJF: 50%ABBV: 50%
100% ABBV50/50100% ASCJF
Portfolio after 10yr
$83.8K
Annual income
$12,515.86/yr
Blended yield
14.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ASCJF
No analyst data
Altman Z
4.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASCJF buys
0
ABBV buys
0
No recent congressional trades found for ASCJF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASCJFABBV
Forward yield105.08%3.06%
Annual dividend / share$0.15$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-38.7%40.6%
Portfolio after 10y$65.2K$102.3K
Annual income after 10y$259.96$24,771.77
Total dividends collected$28.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ASCJF vs ABBV ($10,000, DRIP)

YearASCJF PortfolioASCJF Income/yrABBV PortfolioABBV Income/yrGap
1$17,141$6,441.32$11,550$430.00+$5.6KASCJF
2$24,667$6,325.51$13,472$627.96+$11.2KASCJF
3$31,608$5,214.82$15,906$926.08+$15.7KASCJF
4$37,649$3,828.29$19,071$1,382.55+$18.6KASCJF
5$42,897$2,612.38$23,302$2,095.81+$19.6KASCJF
6$47,605$1,705.23$29,150$3,237.93+$18.5KASCJF
7$52,021$1,084.14$37,536$5,121.41+$14.5KASCJF
8$56,342$678.72$50,079$8,338.38+$6.3KASCJF
9← crossover$60,707$421.13$69,753$14,065.80$9.0KABBV
10$65,216$259.96$102,337$24,771.77$37.1KABBV

ASCJF vs ABBV: Complete Analysis 2026

ASCJFStock

Established in 2005 and listed on the Euronext Oslo Stock Exchange (ticker: AMSC), AMSC is a yield driven maritime investment company. The Company has an ambition to pay attractive dividends to its shareholders. Further information is available at www.amscasa.com.

Full ASCJF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ASCJF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASCJF vs SCHDASCJF vs JEPIASCJF vs OASCJF vs KOASCJF vs MAINASCJF vs JNJASCJF vs MRKASCJF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.